Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 182
Filtrar
1.
J Pediatr ; 245: 222-226.e2, 2022 06.
Artigo em Inglês | MEDLINE | ID: mdl-35189177

RESUMO

Associations between fetal exposure to antidepressants and neonatal hypotonia were studied using VigiBase and the French PharmacoVigilance Database. We identified significant associations between neonatal hypotonia and clomipramine, venlafaxine, and imipramine. Reports from the French database implicated prolonged fetal exposure. Neonatal hypotonia may be associated with in utero exposure to antidepressants.


Assuntos
Doenças do Recém-Nascido , Doenças Neuromusculares , Antidepressivos/efeitos adversos , Humanos , Recém-Nascido , Hipotonia Muscular/induzido quimicamente
2.
Forensic Sci Int ; 325: 110858, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34091410

RESUMO

France is the country with the highest prevalence of cannabis use in Europe, despite the fact that cannabis has not been legalized. This prevalence is still increasing along with THC content in cannabis products. In the meantime, unintentional cannabis poisoning by ingestion in toddlers is constantly rising. The aim of this study was to document children's cannabis poisoning biologically and clinically. Plasma and urine samples were extracted by solid phase extraction and analyzed by liquid chromatography coupled to tandem mass spectrometry. Children under 4 years old admitted in pediatric emergency departments for cannabis intoxication between February 1st 2019 and January 31st 2020 were included in this study. Twenty-six children were included (14 female and 12 male), the mean age was 17 months (10-41 months). THC, 11-OH-THC and THC-COOH plasma concentrations ranged from 2.9 to 93 ng/mL, 2.6-65 ng/mL and 29-914 ng/mL, respectively. The most frequent symptoms were drowsiness and hypotonia. Six critical cases were observed: 5 coma and 1 respiratory depression. All children having THC plasma concentrations over 60 ng/mL were in coma. Cannabis poisoning in toddlers become more frequent, 9 cases/year were reported in Marseille in 2007 and 26 cases/year in this study. There is a rising in severe clinical cases, particularly coma. These observations could be explained by an increase in THC content in cannabis products, and a trivialization of cannabis consumption. The unintentional ingestion of cannabis by children is a serious public health concern, and cannabis legalization could worsen this problem.


Assuntos
Acidentes/estatística & dados numéricos , Cannabis/intoxicação , Canabinoides/sangue , Pré-Escolar , Coma/induzido quimicamente , Serviço Hospitalar de Emergência , Fadiga/induzido quimicamente , Feminino , França/epidemiologia , Humanos , Lactente , Masculino , Hipotonia Muscular/induzido quimicamente , Intoxicação/epidemiologia , Insuficiência Respiratória/induzido quimicamente
3.
Pediatr. aten. prim ; 22(87): 283-286, jul.-sept. 2020.
Artigo em Espanhol | IBECS | ID: ibc-200816

RESUMO

El episodio hipotonía-hiporrespuesta (EHH) es un tipo muy inusual de efecto adverso después de la vacunación. Se ha observado con mayor frecuencia tras las vacunas de células enteras contra la tosferina. El EHH se caracteriza por el inicio repentino de hipotonía, hiporrespuesta y el cambio de color de la piel (palidez o cianosis) en las primeras 48 horas después de la administración de una vacuna en niños. Se ha descrito que los episodios pueden durar entre 6 y 30 minutos. Se desconoce la patogénesis. Aunque se ha clasificado dentro de las reacciones adversas graves, no se han demostrado efectos a largo plazo y no se contraindica la administración de una nueva dosis de la vacuna, si así está indicado para completar el calendario de vacunación del niño. Presentamos el caso de una lactante de 5 meses de edad que presentó un EHH tres horas después de la administración de una segunda dosis de la vacuna antimeningocócica B 4CMenB (Bexsero)


Hypotonic-hyporesponsive episode (HHE) is a very unusual type of adverse effect following immunization. HHE has been observed more frequently following whole-cell pertussis vaccines. HHE is characterized by sudden onset of reduced muscle tone, hyporesponsiveness and change of skin colour (paleness or cyanosis) in the first 48 hours after the administration of a vaccine in children. It has been shown that episodes can last between 6 and 30 minutes. The pathogenesis is unknown. Although it has been classified within the severe adverse reactions, long-term effects have not been shown and it does not contraindicate the administration of a new dose of the vaccine, as well as for the vaccination schedule of the child. Introducing the case of a 5-month-old breastfeeding infant who presented a HHE 3 hours after the administration of a second dose of the antimeningococcal B vaccine, 4CMenB (Bexsero)


Assuntos
Humanos , Feminino , Lactente , Hipotonia Muscular/induzido quimicamente , Vacinas Meningocócicas/efeitos adversos , Infecções Meningocócicas/prevenção & controle , Tempo de Reação/efeitos dos fármacos , Conduta do Tratamento Medicamentoso/organização & administração , Fatores de Risco
4.
J Neonatal Perinatal Med ; 11(4): 439-441, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30149475

RESUMO

Neonatal seizures are frequent in neonatal intensive care and the most common cause is perinatal asphyxia. Among other causes, toxin exposure is rare.We present a boy with an uneventful vaginal birth, who presented one hour after birth with apnea, hypotonia, mydriasis, tongue fasciculation, and tonic seizures. There was no hypoxic ischemic encephalopathy and brain imaging was normal. Toxicology screening revealed a toxic concentration of lidocaine in his blood. The intoxication was transplacental, as a cord blood sample confirmed the toxic level. This was probably due to maternal perineal nerve block with lidocaine.Perineal local infiltration of lidocaine is not without risk for the newborn. Toxicology screen remains an important tool in the work-up of neonatal seizures and sudden unexpected postnatal collapse.


Assuntos
Anestesia Obstétrica/efeitos adversos , Apneia/induzido quimicamente , Lidocaína/efeitos adversos , Troca Materno-Fetal/efeitos dos fármacos , Hipotonia Muscular/induzido quimicamente , Convulsões/induzido quimicamente , Adulto , Apneia/embriologia , Feminino , Humanos , Recém-Nascido , Terapia Intensiva Neonatal , Lidocaína/sangue , Masculino , Hipotonia Muscular/embriologia , Bloqueio Nervoso , Gravidez , Convulsões/embriologia , Resultado do Tratamento
7.
Hum Vaccin Immunother ; 13(6): 1-4, 2017 06 03.
Artigo em Inglês | MEDLINE | ID: mdl-28301267

RESUMO

Hypotonic-hyporesponsive (HHE) episodes are known and recognized phenomena, which typically occur within 48 hours of immunisation..Our aim is to describe 12 cases of HHE brought to the Center of Pediatric Sleep Medicine, with attention to the clinical features of the episode and their follow-up. Medical charts of infants visited between 2005-2015 were reviewed. Twelve infants showed a HHE using HHE using Brighton Collaboration Criteria. All infants received a Hexavalent diphtheria -tetanus -pertussis acellular component -hepatitis B-,inactivated poliovirus- Haemophilus influenzae type-b conjugate vaccine. Five out of 12 were brought to Emergency Department, where 2 were symptomatic (one was hyporeactive, the other had fever). No infant died during the episode, or the follow-up, nor developed neurological disease after subsequent vaccinations. HHE are confirmed as benign events, even after administration of hexavalent vaccination, devoid of negative neuropsychomotor outcome.


Assuntos
Vacina contra Difteria, Tétano e Coqueluche/administração & dosagem , Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos , Vacinas Anti-Haemophilus/administração & dosagem , Vacinas Anti-Haemophilus/efeitos adversos , Vacinas contra Hepatite B/administração & dosagem , Vacinas contra Hepatite B/efeitos adversos , Transtornos Mentais/induzido quimicamente , Hipotonia Muscular/induzido quimicamente , Palidez/induzido quimicamente , Vacina Antipólio de Vírus Inativado/administração & dosagem , Vacina Antipólio de Vírus Inativado/efeitos adversos , Feminino , Humanos , Lactente , Masculino , Resultado do Tratamento , Vacinas Combinadas/administração & dosagem , Vacinas Combinadas/efeitos adversos
9.
Neuropharmacology ; 117: 85-92, 2017 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-28161374

RESUMO

Inhibitory GABAergic and glycinergic neurotransmission in the spinal cord play a central role in the regulation of neuronal excitability, by maintaining a balance with the glutamate-mediated excitatory transmission. Glutamatergic agonists infusion in the spinal cord induce motor neuron death by excitotoxicity, leading to motor deficits and paralysis, but little is known on the effect of the blockade of inhibitory transmission. In this work we studied the effects of GABAergic and glycinergic blockade, by means of microdialysis perfusion (acute administration) and osmotic minipumps infusion (chronic administration) of GABA and glycine receptors antagonists directly in the lumbar spinal cord. We show that acute glycinergic blockade with strychnine or GABAergic blockade with bicuculline had no significant effects on motor activity and on motor neuron survival. However, chronic bicuculline infusion, but not strychnine, induced ipsilateral gait alterations, phalange flaccidity and significant motor neuron loss, and these effects were prevented by AMPA receptor blockade with CNQX but not by NMDA receptor blockade with MK801. In addition, we demonstrate that the chronic infusion of bicuculline enhanced the excitotoxic effect of AMPA, causing faster bilateral paralysis and increasing motor neuron loss. These findings indicate a relevant role of GABAergic inhibitory circuits in the regulation of motor neuron excitability and suggest that their alterations may be involved in the neurodegeneration processes characteristic of motor neuron diseases such as amyotrophic lateral sclerosis.


Assuntos
Bicuculina/toxicidade , Antagonistas GABAérgicos/toxicidade , Atividade Motora/efeitos dos fármacos , Neurônios Motores/efeitos dos fármacos , Degeneração Neural/induzido quimicamente , Medula Espinal/efeitos dos fármacos , Estricnina/toxicidade , 6-Ciano-7-nitroquinoxalina-2,3-diona/farmacologia , Animais , Atrofia/induzido quimicamente , Bicuculina/antagonistas & inibidores , Maleato de Dizocilpina/farmacologia , Interações Medicamentosas , Marcha/efeitos dos fármacos , Masculino , Hipotonia Muscular/induzido quimicamente , Ratos , Receptores de Glicina/antagonistas & inibidores , Estricnina/antagonistas & inibidores , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiônico/toxicidade
10.
Ann Biol Clin (Paris) ; 74(3): 348-52, 2016 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-27237806

RESUMO

Baclofen is an agonist of peripheral and central B gamma-aminobutyric acid receptors, whose activation causes a myorelaxation and a powerfull depression of the central nervous system. Moreover, it has an action against addiction, in reducing craving. Commercialized since 1975 in France, to control muscle spasticity due to medullar affection or multiple sclerosis, it receives a temporary recommendation of use in march 2014, as a last-line adjuvant treatment in alcohol withdrawal. Beyond its therapeutic use, baclofen is involved in many self-induced intoxications. We report the case of a patient who develops, after a massive ingestion of baclofen (supposed dose ingested: 1 200 mg), a hypotonic and calm coma, requiring her admission in our intensive care unit, and then a status epilepticus.


Assuntos
Baclofeno/intoxicação , Coma/induzido quimicamente , Overdose de Drogas/diagnóstico , Comportamento Autodestrutivo , Estado Epiléptico/induzido quimicamente , Coma/complicações , Feminino , França , Humanos , Pessoa de Meia-Idade , Hipotonia Muscular/induzido quimicamente , Hipotonia Muscular/complicações , Comportamento Autodestrutivo/complicações , Comportamento Autodestrutivo/diagnóstico , Estado Epiléptico/complicações , Síndrome de Abstinência a Substâncias/complicações
11.
J Vasc Access ; 17(4): e82-4, 2016 Jul 12.
Artigo em Inglês | MEDLINE | ID: mdl-27056029

RESUMO

INTRODUCTION: Percutaneously inserted central venous catheters (epicutaneo-cava-catheter - ECC) are widely used in neonatal intensive care, facilitating the parenteral nutrition and the treatment of critically ill newborns. This invasive procedure is regarded as safe and associated with low complication rate. Possible life-threatening complications may result from malpositioning of ECC. Paraspinal misplacement of ECC is one of the most serious complications. CASE PRESENTATION: The authors report a case of misplacement of ECC inserted via left saphenous vein for intravenous feeding. A plane radiograph performed after the procedure showed the line tip at L3-L4 level, supposed to indicate location of the catheter in the vena cava inferior. Three days later, the infant developed neurologic symptoms (lethargy, hypotonia, seizures). Lumbar puncture revealed milky fluid containing parenteral nutrition solution. The infusion was stopped. X-ray with contrast showed the catheterization of the left ascending lumbar vein draining the vertebral venous plexuses. The contrast was highlighting the epidural space. The line was immediately removed resulting in improvement in patient's condition and resolution of all neurological symptoms. There was no sequela of this infiltration and the baby had an uneventful recovery. Follow-up at the age of 12 months showed normal development. CONCLUSIONS: A percutaneous catheter inserted via a lower limb may inadvertently enter the ascending lumbar vein. As previously reported, a catheter inserted via the left lower limb is a risk factor of this malposition. The life-threatening complications may be avoided by careful verification of ECC position (lateral x-ray, contrast examination). Plain radiography alone may not be sufficient for tip localization.


Assuntos
Cateterismo Periférico/efeitos adversos , Líquido Cefalorraquidiano/química , Recém-Nascido Prematuro , Erros Médicos , Soluções de Nutrição Parenteral/efeitos adversos , Nutrição Parenteral/efeitos adversos , Remoção de Dispositivo , Espaço Epidural/diagnóstico por imagem , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Letargia/líquido cefalorraquidiano , Letargia/induzido quimicamente , Hipotonia Muscular/líquido cefalorraquidiano , Hipotonia Muscular/induzido quimicamente , Nutrição Parenteral/métodos , Soluções de Nutrição Parenteral/administração & dosagem , Gravidez , Gravidez de Gêmeos , Convulsões/líquido cefalorraquidiano , Convulsões/induzido quimicamente , Punção Espinal , Resultado do Tratamento , Veia Cava Inferior/diagnóstico por imagem
12.
Am J Obstet Gynecol ; 213(3): 424.e1-5, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26026919

RESUMO

OBJECTIVE: Research on immediate neonatal resuscitation suggests that maternal magnesium exposure may be associated with increased risk of low Apgar scores, hypotonia, and neonatal intensive care unit admission. However, not all studies support these associations. Our objective was to determine whether exposure to magnesium at the time of delivery affects initial neonatal resuscitation. STUDY DESIGN: This is a secondary analysis of the Randomized Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy that evaluated whether the study drug (magnesium or placebo) that was administered at the time of delivery was associated with increased risk for a composite adverse neonatal resuscitation outcome (5-minute Apgar score <7, oxygen administration in the delivery room, intubation, chest compressions, hypotension, and hypotonicity). A subgroup analysis was performed among patients who delivered at ≥30 weeks of gestation. Log-linear regression was used to control for possible confounders. RESULTS: Data for 1047 patients were analyzed, of whom 461 neonates (44%) were exposed to magnesium. There was no increased risk for the primary composite outcome associated with magnesium exposure. Individual adverse neonatal outcomes and other secondary short-term neonatal outcomes that were evaluated also did not demonstrate an association with magnesium exposure. CONCLUSION: Exposure to magnesium sulfate did not affect neonatal resuscitation or other short-term outcomes. These findings may be useful in planning neonatal care and patient counseling.


Assuntos
Paralisia Cerebral/prevenção & controle , Doenças do Prematuro/prevenção & controle , Sulfato de Magnésio/efeitos adversos , Fármacos Neuroprotetores/efeitos adversos , Nascimento Prematuro , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Ressuscitação , Índice de Apgar , Feminino , Humanos , Hipotensão/induzido quimicamente , Recém-Nascido , Recém-Nascido Prematuro , Modelos Lineares , Sulfato de Magnésio/uso terapêutico , Hipotonia Muscular/induzido quimicamente , Fármacos Neuroprotetores/uso terapêutico , Gravidez
13.
Am J Case Rep ; 16: 232-5, 2015 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-25895118

RESUMO

BACKGROUND: Baclofen is a centrally acting gamma-aminobutyric acid agonist used for the symptomatic relief of skeletal muscle spasm and spasticity in traumatic spinal cord lesions, multiple sclerosis, cerebral palsy, and stroke. It is also used in the treatment of chronic hiccups and cocaine abuse. Baclofen-induced central nervous system depression is rare at the usual therapeutic doses. However, patients with impaired renal function are at a higher risk of developing baclofen toxicity, even at a lower dose. CASE REPORT: A 57-year-old woman with end-stage renal disease on hemodialysis was admitted to our emergency department with progressive confusion and a generalized decrease in muscular tone. There was no obvious metabolic or infectious etiology that could have explained her condition. A comprehensive laboratory and imaging workup was negative. A review of her medication showed that she had recently been prescribed baclofen for muscular spasm. She was diagnosed with baclofen toxicity and was treated with emergent hemodialysis, which improved her mental status and her decreased muscle tone. Repeated sessions of hemodialysis administered on her second and third days of admission ultimately produced sustained clinical improvement and a complete return to her baseline mental status. She was subsequently discharged home with instructions to stay off baclofen. CONCLUSIONS: Baclofen toxicity is an under-diagnosed condition, especially in patients with renal dysfunction. Physicians should consider baclofen toxicity in patients with suboptimal kidney function on baclofen who present with altered mental status. Emergent hemodialysis and intensive care unit monitoring is recommended.


Assuntos
Baclofeno/efeitos adversos , Encefalopatias/induzido quimicamente , Falência Renal Crônica/complicações , Hipotonia Muscular/induzido quimicamente , Espasticidade Muscular/tratamento farmacológico , Baclofeno/uso terapêutico , Encefalopatias/diagnóstico , Feminino , Humanos , Pessoa de Meia-Idade , Hipotonia Muscular/diagnóstico , Relaxantes Musculares Centrais/efeitos adversos , Relaxantes Musculares Centrais/uso terapêutico , Espasticidade Muscular/etiologia
15.
Arch Pediatr ; 22(1): 43-6, 2015 Jan.
Artigo em Francês | MEDLINE | ID: mdl-25466782

RESUMO

Consultations at pediatric emergency units for acute consciousness alterations is frequent. Miscellaneous causes include cranial trauma, meningoencephalitis, metabolic disorders, drugs, or other intoxications. We report here eight cases of infants who were brought to the emergency division due to acute consciousness failure after accidental ingestion of hashish, confirmed by urinary dosage of Δ9-tetrahydrocannabinol. This series of under 24-month-old infants only emphasizes the value of screening for cannabis in urine in cases of abnormal consciousness and/or abnormal behavior in an infant.


Assuntos
Acidentes , Cannabis/efeitos adversos , Dronabinol/urina , Serviço Hospitalar de Emergência , Feminino , Humanos , Lactente , Masculino , Hipotonia Muscular/induzido quimicamente , Taquicardia/induzido quimicamente , Inconsciência/induzido quimicamente
16.
Sleep ; 38(6): 907-17, 2015 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-25325487

RESUMO

STUDY OBJECTIVES: REM sleep behavior disorder (RBD) is associated with antidepressant treatment, especially in younger patients; but quantitative REM sleep without atonia (RSWA) analyses of psychiatric RBD patients remain limited. We analyzed RSWA in adults receiving antidepressants, with and without RBD. DESIGN: We comparatively analyzed visual, manual, and automated RSWA between RBD and control groups. RSWA metrics were compared between groups, and regression was used to explore associations with clinical variables. SETTING: Tertiary-care sleep center. PARTICIPANTS: Participants included traditional RBD without antidepressant treatment (n = 30, 15 Parkinson disease [PD-RBD] and 15 idiopathic); psychiatric RBD receiving antidepressants (n = 30); and adults without RBD, including antidepressant-treated psychiatric (n = 30), untreated psychiatric (n = 15), and OSA (n = 60) controls. INTERVENTIONS: N/A. MEASUREMENTS AND RESULTS: RSWA was highest in traditional and psychiatric RBD, intermediate in treated psychiatric controls, and lowest in untreated psychiatric and OSA controls (P < 0.01). RSWA distribution and type also differed between antidepressant-treated patients having higher values in anterior tibialis, and PD-RBD with higher submentalis and tonic RSWA. Psychiatric RBD had significantly younger age at onset than traditional RBD patients (P < 0.01). CONCLUSIONS: Antidepressant treatment was associated with elevated REM sleep without atonia (RSWA) even without REM sleep behavior disorder (RBD), suggesting that antidepressants, not depression, promote RSWA. Differences in RSWA distribution and type were also seen, with higher anterior tibialis RSWA in antidepressant-treated patients and higher tonic RSWA in Parkinson disease-RBD patients, which could aid distinction between RBD subtypes. These findings suggest that antidepressants may mediate different RSWA mechanisms or, alternatively, that RSWA type and distribution evolve during progressive neurodegeneration. Further prospective RSWA analyses are necessary to clarify the relationships between antidepressant treatment, psychiatric disease, and RBD.


Assuntos
Antidepressivos/farmacologia , Tono Muscular/efeitos dos fármacos , Transtorno do Comportamento do Sono REM/fisiopatologia , Sono REM/efeitos dos fármacos , Adulto , Idoso , Idoso de 80 Anos ou mais , Antidepressivos/efeitos adversos , Depressão/complicações , Depressão/tratamento farmacológico , Depressão/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Hipotonia Muscular/induzido quimicamente , Músculo Esquelético/efeitos dos fármacos , Doença de Parkinson/complicações , Doença de Parkinson/fisiopatologia , Transtorno do Comportamento do Sono REM/induzido quimicamente , Transtorno do Comportamento do Sono REM/complicações
17.
J Addict Med ; 9(1): 75-7, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25494007

RESUMO

Baclofen is a γ-aminobutyric acid (GABA)-ß receptor agonist with a muscle relaxant effect. It increases GABA activity and reduces the production of glutamate and dopamine. The GABA precursor γ-hydroxybutyrate (GHB) has gained popularity as a drug of abuse. For the first time, we report a case of a GHB-dependent patient, who ingested several days' doses of baclofen (80 mg) simultaneously with 0.3 L (215 g) of illicit GHB. Baclofen (40 mg/d) was prescribed to prevent relapse after a successful detoxification. The patient developed a rapid coma (E2M5V1 with oxygen support), bradypnea, and hypotonia. Physicians should be alert to the danger of this combination because of the hazards of coma and respiratory distress.


Assuntos
Baclofeno/efeitos adversos , Coma/induzido quimicamente , Agonistas dos Receptores de GABA-B/efeitos adversos , Hipotonia Muscular/induzido quimicamente , Síndrome do Desconforto Respiratório/induzido quimicamente , Oxibato de Sódio/efeitos adversos , Feminino , Humanos , Adulto Jovem
18.
Arch Pediatr ; 21(2): 198-200, 2014 Feb.
Artigo em Francês | MEDLINE | ID: mdl-24411570

RESUMO

We report a case of clonidine poisoning in a breastfed newborn. At 2 days of life, this boy presented a consciousness deficit with drowsiness, hypotonia, and suspected generalized seizures. There were no cardiorespiratory problems outside of progressive central apneas beginning the 5th day. Further initial investigations were normal (extensive biological exams, cranial ultrasonography and transfontanellar Doppler, electroencephalography, and brain MRI study), excluding the main causes of neonatal hypotonia (encephalitis, infection, metabolic disorder). However, new medical questioning revealed maternal daily intake of 0.15 mg clonidine for hypertension during and after pregnancy. Since it was impossible to quantify clonidine quantification in newborn serum and breast milk, a weaning test was performed the 9th day. Twenty-four hours after cessation of breastfeeding, complete regression of symptoms was obtained. Poisoning by clonidine after fetal and neonatal exposure through breast milk is rare but severe enough to simulate a neurological disease. Diagnosis is based on the search for drug use and the cessation of breastfeeding if doubt persists. Recovery of normal examination results is then rapid and complete.


Assuntos
Clonidina/farmacocinética , Clonidina/intoxicação , Transtornos da Consciência/induzido quimicamente , Hipertensão Induzida pela Gravidez/sangue , Hipertensão Induzida pela Gravidez/tratamento farmacológico , Troca Materno-Fetal/fisiologia , Leite Humano/metabolismo , Hipotonia Muscular/induzido quimicamente , Fases do Sono/efeitos dos fármacos , Clonidina/uso terapêutico , Transtornos da Consciência/sangue , Diagnóstico Diferencial , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Convulsões/sangue , Convulsões/induzido quimicamente , Apneia do Sono Tipo Central/sangue , Apneia do Sono Tipo Central/induzido quimicamente
19.
Turk J Pediatr ; 56(4): 427-9, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25818964

RESUMO

Hypotensive-hyporesponsive episodes are rare events after immunizations performed for diphtheria, tetanus, Haemophilus influenzae type b and hepatitis B virus vaccines, but most of the reported episodes have been associated with pertussis-containing vaccines. We report the case of a 3-month-old girl, previously healthy otherwise, presenting with the unusual event of a hypotonic-hyporesponsive episode after vaccination with the 13-valent pneumococcal vaccine. Diagnosis was established after a thorough evaluation of the patient and by exclusion of other clinical conditions.


Assuntos
Hipotonia Muscular/induzido quimicamente , Vacinas Pneumocócicas/efeitos adversos , Vacinação/efeitos adversos , Feminino , Humanos , Lactente , Infecções Pneumocócicas/prevenção & controle , Vacinas Conjugadas
20.
Pediatr Emerg Care ; 29(11): 1207-9, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24196091

RESUMO

Topical ocular medications have been widely prescribed and successfully used in children for the management of different ophthalmic disorders. We present 2 infants admitted to our pediatric intensive care unit who developed altered state of consciousness, hypotonia, hypothermia, bradycardia, and apnea after instillation of ophthalmic drops. The second infant also had hypotension and broncho-obstruction. Few days before admission, both infants were diagnosed with congenital glaucoma, and topical antiglaucoma treatment was initiated. Ophthalmic drops with brimonidine and brinzolamide were prescribed to both patients, whereas the second infant also received topical timolol. After elimination of other possible causes, the diagnosis of intoxication with topical antiglaucoma medications was established. After discontinuation of eye drops and vigorous symptomatic treatment, both infants recovered without sequels. Topically applied ophthalmic drops may cause life-threatening systemic adverse effects in infants, such as central nervous system depression and cardiogenic shock. Moreover, these 2 patients illustrate the importance of careful evaluation of all topical medications and their consideration as possible causes of the derangements in critically ill infants.


Assuntos
Apneia/induzido quimicamente , Transtornos da Consciência/induzido quimicamente , Soluções Oftálmicas/intoxicação , Quinoxalinas/intoxicação , Choque Cardiogênico/induzido quimicamente , Sulfonamidas/intoxicação , Tiazinas/intoxicação , Timolol/intoxicação , Absorção , Administração Oftálmica , Bradicardia/induzido quimicamente , Tartarato de Brimonidina , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Emergências , Feminino , Glaucoma/congênito , Glaucoma/tratamento farmacológico , Humanos , Hipotermia/induzido quimicamente , Lactente , Hipotonia Muscular/induzido quimicamente , Mucosa Nasal/fisiologia , Soluções Oftálmicas/farmacocinética , Quinoxalinas/administração & dosagem , Quinoxalinas/farmacocinética , Quinoxalinas/uso terapêutico , Sulfonamidas/administração & dosagem , Sulfonamidas/farmacocinética , Sulfonamidas/uso terapêutico , Tiazinas/administração & dosagem , Tiazinas/farmacocinética , Tiazinas/uso terapêutico , Timolol/administração & dosagem , Timolol/farmacocinética , Timolol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...